Dec 2 2009
Ohr Pharmaceutical Inc. (OTCBB/exchange>: OHRP), announced that interim data from the company's ongoing Phase II clinical trial of OHR/AVR118 for the treatment of Cachexia, will be presented at the 5th annual meeting of the Society on Cachexia and Wasting Disorders (SCWD), which will be held in Barcelona December 5 - December 8, 2009.
The abstract was selected for oral presentation on Monday, December 7, 2009 in the "Clinical Trials: late-breaking approaches" session.